A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Running, not enrolling · Phase 3
Conditions studied: Metastatic Non-small Cell Lung Cancer
In brief
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Key facts
- Study ID
- NCT05984277
- Run by
- AstraZeneca
- People needed
- 895
- Starts
- 2023-10-24
- Expected to finish
- 2029-02-28
- Last updated by the study team
- 2026-07-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — São Paulo, Brazil
- Research Site — Calgary, Alberta, Canada
- Research Site — Edmonton, Alberta, Canada
- Research Site — Winnipeg, Manitoba, Canada
- Research Site — Halifax, Nova Scotia, Canada
- Research Site — Barrie, Ontario, Canada
- Research Site — Oshawa, Ontario, Canada
- Research Site — Toronto, Ontario, Canada
- Research Site — Lévis, Quebec, Canada
- Research Site — Trois-Rivières, Quebec, Canada
- Research Site — Chicoutimi, Canada
- Research Site — Beijing, China
- Research Site — Beijing, China
- Research Site — Beijing, China
- Research Site — Changchun, China
- Research Site — Changsha, China
- Research Site — Chengdu, China
- Research Site — Chengdu, China
- Research Site — Chongqing, China
- Research Site — Fuzhou, China
- Research Site — Guangzhou, China
- Research Site — Hangzhou, China
- Research Site — Hangzhou, China
- Research Site — Hefei, China
- Research Site — Santa Cruz do Sul, Brazil
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.